BCI
ESPR

Brinker Capital Investments’s Esperion Therapeutics ESPR Stock Holding History

Brinker Capital Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,974
Closed -$33.3K – 1636
2023
Q1 		$33.3K Buy
+20,974
New +$108K ﹤0.01% 1549
2020
Q4 		– Sell
-5,929
Closed -$220K – 1065
2020
Q3 		$220K Buy
+5,929
New +$235K ﹤0.01% 1086

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Brinker Capital Investments's ESPR Position: Q2 2023 in Review

Brinker Capital Investments sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 20,974 shares — an estimated $33.3K sold.

Brinker Capital Investments first reported a position in ESPR in Q3 2020 and held it in 2 quarters. The position peaked at $220K in Q3 2020. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

  • Brinker Capital Investments reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Brinker Capital Investments sold 20,974 Esperion Therapeutics shares in Q2 2023, an estimated $33.3K.
  • Brinker Capital Investments first reported a position in Esperion Therapeutics in Q3 2020 and held it in 2 quarters.
  • Brinker Capital Investments's Esperion Therapeutics position peaked at $220K in Q3 2020.
  • 124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Brinker Capital Investments's 13F filing for Q2 2023, filed 31 Jul 2025.